NCT05514132 2026-03-09
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
AstraZeneca
AstraZeneca
PrECOG, LLC.
Inimmune Corporation
Dana-Farber Cancer Institute
University Health Network, Toronto
NeoTX Therapeutics Ltd.
Baylor College of Medicine
AstraZeneca